The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
Expansion into the supply chain side of the drug industry is ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback